Breast cancer subtypes and the risk of distant metastasis at initial diagnosis: a population-based study

• DOI: 10.2147/cmar.s176763
• Publication Date: 2018-11-04T18:21:30Z
• Authors: Weikai Xiao; Shaoquan Zheng; Anli Yang; Xingcai Zhang; Yutian Zou; Hailin Tang; Xiaoming Xie
• Keywords: 0301 basic medicine; 2. Zero hunger; 0303 health sciences; Molecular subtypes; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; 3. Good health; 03 medical and health sciences; breast cancer; 0302 clinical medicine; distant metastasis; Cancer Management and Research; metastatic sites; prognosis; RC254-282; Original Research

It was unclear whether breast cancer subtypes are associated with the risk of site-specific metastases. This study aimed to evaluate relationship between molecular and distant metastatic sites their prognostic significance.We identified 295,213 patients invasive from 2010 2014 using Surveillance, Epidemiology End Results database. Subtypes were classified into four categories: hormone receptor (HR+)/human epidermal growth factor 2 (HER2-), HR+/HER2+, HR-/HER2+, triple-negative (HR-/HER2-). Logistic regression used assess association metastasis location subtypes. Multivariate Cox models estimate overall survival (OS) related factors.According our study, 3.28%, 1.52%, 1.20%, 0.35% newly diagnosed cancers presented bone, lung, liver, brain metastases at diagnosis, respectively. Both significantly affected OS after metastasis. In multivariate analysis, HR+/HER2+ subtype (OR as compared HR+/HER2- subtype, 1.30 [95% CI, 1.22-1.39]) correlated elevated bone risk, whereas HR-/HER2+ did not. HER2+ (HR+/HER2+ HR-/HER2+) higher rates brain, lung metastases, while highest OR observed in liver Triple-negative tumors had a rate (OR, 1.95 1.61-2.35]), 1.35 1.20-1.51]), 1.34 1.21-1.47]), but lower 0.64 0.59-0.69]) than HR+/HER2-tumors.Breast different patterns confer impacts. Molecular can identify increased